Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations

Delayed-release dimethyl fumarate (DMF), also known as gastroresistant DMF, is the most recently approved oral disease-modifying treatment (DMT) for relapsing multiple sclerosis. Two randomized clinical trials (Determination of the Efficacy and Safety of Oral Fumarate in Relapsing–Remitting MS [DEFI...

Descripción completa

Detalles Bibliográficos
Autores principales: Prosperini, Luca, Pontecorvo, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780395/
https://www.ncbi.nlm.nih.gov/pubmed/27042079
http://dx.doi.org/10.2147/TCRM.S85099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780395/
https://www.ncbi.nlm.nih.gov/pubmed/27042079
http://dx.doi.org/10.2147/TCRM.S85099

Ejemplares similares